Logo

Phenomenex Clarity LC Columns for Synthetic Oligo Analysis

Nov 30, 2016

Phenomenex has launched two new products for characterization and purification of synthetic oligonucleotides, the Clarity Oligo-XT C18 column and the Clarity Oligo-SAX column.

The products will be offered as part of the firm's Clarity BioSolutions portfolio of columns for chromatographic analysis.

The Oligo-XT C18 column is intended for high-efficiency reversed-phase liquid chromatography analysis and purification. Featuring new and robust core-shell media, it offers the separation power to resolve closely related synthetic oligos and the sensitivity to improve quantitation by mass spectrometry. The columns are available in directly scalable 1.7-micrometer, 2.5-micrometer, and 5-micrometer particle sizes. 

The Oligo-SAX is a high-resolution strong anion exchanger for characterization, featuring new rugged non-porous particles for improved column lifetimes. It is engineered for performance at high pH and temperatures up to 85° C. It comes in a 5-micrometer particle size for analytical characterization.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.